4 August 2023
Scientific research has always been at the forefront of driving progress and innovation, transforming the way we understand the world around us. Within this vast landscape of knowledge, certain areas have stood out for their significant impact on human health and well-being. One such area is Antioxidants & Redox Signaling, a field dedicated to unraveling the intricate mechanisms of cellular protection and redox regulation. In this blog, we celebrate the latest achievements in this fascinating field, including the work of Dr. Paula I. Moreira, a distinguished researcher who has made a profound impact in this domain. In addition to her research contributions in the field of Antioxidants & Redox Signaling, Dr. Paula I. Moreira also serves as a deputy editor of the Journal of Alzheimer's Disease.
Rosalind Franklin Society Awards in Science
Recognizing the underrepresentation of women and minorities in science, Mary Ann Liebert, Inc., in collaboration with the Rosalind Franklin Society, introduced the prestigious RFS Awards in Science. These annual awards aim to celebrate and acknowledge exceptional research published by women and underrepresented minorities in science across various peer-reviewed journals. Among the recipients of the RFS Awards in Science for Antioxidants & Redox Signaling is Dr. Paula I. Moreira, whose contributions have made a significant impact in understanding and combating neurodegenerative diseases.
Meet Paula I. Moreira
Dr. Paula I. Moreira's journey in science began with her passion for biomedical sciences, leading her to pursue a PhD at the esteemed University of Coimbra in Portugal. Since then, she has been making waves in the scientific community, holding the position of a professor of physiology at the Faculty of Medicine and serving as a principal investigator at the Center for Neuroscience and Cell Biology, both at the University of Coimbra.
Dr. Moreira's research focuses on the critical role of energy metabolism, particularly within mitochondria, and the signaling pathways mediated by metabolic hormones in brain changes associated with metabolic disorders and neurodegenerative diseases, with a special emphasis on Alzheimer's disease. This research involves exploring the preventive and therapeutic potential of pharmacological and nonpharmacological strategies, such as mitochondrial modulators and hypoxic preconditioning.
Groundbreaking Research - A Focus on Alzheimer's Disease
One of Dr. Moreira's most notable works is the co-authored paper titled "Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria." This groundbreaking research sheds light on the potential of hypoxic preconditioning - a process in which cells are exposed to low oxygen levels temporarily - in mitigating the Alzheimer's disease-like phenotype in rats. By focusing on the role of mitochondria, the cellular powerhouses responsible for energy production, Dr. Moreira's work highlights a promising avenue for future research and therapeutic approaches.
Dr. Moreira's dedication to understanding the intricate workings of cellular energy metabolism and its implications in neurodegenerative diseases has the potential to revolutionize treatment strategies for Alzheimer's disease and other related conditions. Her findings pave the way for novel therapeutic interventions and preventive measures that could significantly impact the lives of millions of people worldwide.
The Promising Path Ahead: Antioxidants & Redox Signaling and the Power of Inclusive Science
The Antioxidants & Redox Signaling field has made tremendous strides in our understanding of cellular protection and redox regulation, ultimately shaping the future of medical research and treatment. The RFS Awards in Science, along with its recognition of exemplary researchers like Dr. Paula I. Moreira, plays a crucial role in promoting diversity and inclusivity in scientific advancements. With pioneers like Dr. Moreira leading the way, we can look forward to a brighter, healthier future for generations to come.
The Journal of Alzheimers Disease celebrates the impact that dedicated scientists like Dr. Moreira have on shaping the scientific landscape and improving human health. Let us continue to support and encourage diversity in scientific research and foster an environment where groundbreaking discoveries thrive.
George Perry, PhD
Editor-in-Chief, Journal of Alzheimer's Disease
+1 210 458 4450
Pim van Holst
+31 20 688 3355
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 4 according to Journal Citation Reports™ (Clarivate, 2023). www.j-alz.com
ABOUT IOS PRESS
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com